Nanoscope Therapeutics
2:00 PM - 2:15 PM (EST), Tuesday, February 7, 2023 ・ Winter Garden
Nanoscope Therapeutics is a clinical-stage biopharmaceutical company developing gene therapies to cure genetic diseases that cause vision impairment and blindness.
These diseases include Retinitis Pigmentosa, Dry Age-related Macular Degeneration (AMD), and Stargardt Disease. We are developing a proprietary platform technology, employing ambient light-sensitive Multi-Characteristic Opsins (MCO) that has potential to treat a broad range of genetic illnesses.
These diseases include Retinitis Pigmentosa, Dry Age-related Macular Degeneration (AMD), and Stargardt Disease. We are developing a proprietary platform technology, employing ambient light-sensitive Multi-Characteristic Opsins (MCO) that has potential to treat a broad range of genetic illnesses.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Texas
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Gene/Cell Therapy
Lead Product in Development:
MCO-010
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
